GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actavia Life Sciences Inc (OTCPK:RASP) » Definitions » Return-on-Tangible-Asset

Actavia Life Sciences (Actavia Life Sciences) Return-on-Tangible-Asset : -1,024.00% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Actavia Life Sciences Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Actavia Life Sciences's annualized Net Income for the quarter that ended in Mar. 2024 was $-0.38 Mil. Actavia Life Sciences's average total tangible assets for the quarter that ended in Mar. 2024 was $0.04 Mil. Therefore, Actavia Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -1,024.00%.

The historical rank and industry rank for Actavia Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:

RASP' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -9994.39   Med: -438.41   Max: -105.4
Current: -782.69

During the past 11 years, Actavia Life Sciences's highest Return-on-Tangible-Asset was -105.40%. The lowest was -9994.39%. And the median was -438.41%.

RASP's Return-on-Tangible-Asset is ranked worse than
97.55% of 1550 companies
in the Biotechnology industry
Industry Median: -40.42 vs RASP: -782.69

Actavia Life Sciences Return-on-Tangible-Asset Historical Data

The historical data trend for Actavia Life Sciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actavia Life Sciences Return-on-Tangible-Asset Chart

Actavia Life Sciences Annual Data
Trend Jun14 Jun15 Jun16 Mar17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -438.41 -9,994.39 -2,246.15 -1,056.92 -4,909.39

Actavia Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29,231.86 -943.82 -348.87 -970.49 -1,024.00

Competitive Comparison of Actavia Life Sciences's Return-on-Tangible-Asset

For the Biotechnology subindustry, Actavia Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actavia Life Sciences's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actavia Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Actavia Life Sciences's Return-on-Tangible-Asset falls into.



Actavia Life Sciences Return-on-Tangible-Asset Calculation

Actavia Life Sciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Sep. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=-4.443/( (0.085+0.096)/ 2 )
=-4.443/0.0905
=-4,909.39 %

Actavia Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-0.384/( (0.026+0.049)/ 2 )
=-0.384/0.0375
=-1,024.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Actavia Life Sciences  (OTCPK:RASP) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Actavia Life Sciences Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Actavia Life Sciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Actavia Life Sciences (Actavia Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2525, New York, NY, USA, 10170
Rasna Therapeutics Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.

Actavia Life Sciences (Actavia Life Sciences) Headlines

No Headlines